DiscoverOri SpotlightCarl Schoellhammer: viability is the crucial third pillar in CGT
Carl Schoellhammer: viability is the crucial third pillar in CGT

Carl Schoellhammer: viability is the crucial third pillar in CGT

Update: 2024-06-25
Share

Description

In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs).

Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.

Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Carl Schoellhammer: viability is the crucial third pillar in CGT

Carl Schoellhammer: viability is the crucial third pillar in CGT

Ori Biotech